Why is the Rhythm (ASX:RHY) share price climbing 10% today?

Investors appear to be just as excited as the scientists at Rhythm Biosciences about today’s update.

| More on:
Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

The Rhythm Biosciences Ltd (ASX: RHY) share price is on the move during late morning trade on Thursday.

This comes after the medical device company provided an update in regards to its colorectal cancer test kit product, ColoSTAT.

At the time of writing, the Rhythm share price is up 10% to $1.32 apiece.

Rhythm progresses towards commercialisation of test kit

In today’s release, Rhythm advised it has continued to conduct confirmatory testing on its ColoSTAT proprietary medical device.

Previously, Rhythm achieved positive results from its Study 6 findings in mid-March. It stated that the ColoSTAT prototype test kit demonstrates an accuracy of 84% sensitivity at 95% specificity.

This means the ColoSTAT blood test is 33% more accurate than the current market standard faecal tests.

Rhythm stated that it is advancing its approval process with the Therapeutic Goods Administration (TGA) for ColoSTAT. Achieving regulatory approval is the final hurdle for entering the Australian market.

In Europe, Rhythm has submitted its CE Mark application and is anticipating approval by end of the year. The company notes that the recent confirmatory testing is designed to support the criteria required to obtain a CE Mark.

A final study is underway following the completion of the patient recruitment phase last month. Rhythm expects to deliver the report in the first half of 2022.

Rhythm CEO, Glenn Gilbert, said:

Our visible path to market is emerging as our ongoing testing program continues to provide the company with confidence moving through the regulatory phase. The high accuracy of our cancer diagnostics technology has the potential to deliver positive outcomes for millions of people around the world. This is an exciting time for all stakeholders as we focus on the massive global market opportunity ahead of us.

More on ColoSTAT and colorectal cancer

ColoSTAT is an experimental test kit being trialled as a low-cost and easy-to-use blood test that detects colorectal cancer.

An estimated 850,000 people lose their lives from colorectal cancer each year.

In the United States, Europe, and Australia, more than 130 million people aged 50-74 years have not been tested for colorectal cancer. This represents an addressable market opportunity worth more than $6.5 billion.

Rhythm share price snapshot

The Rhythm share price has accelerated by 500% in the past 12 months, reflecting positive investor sentiment.

The shares reached an all-time high of $1.675 in March before some profit-taking investors swooped in.

At today’s price, Rhythm presides a market capitalisation of roughly $281.9 million with 208.8 million shares on issue.

Should you invest $1,000 in Rhythm Biosensors right now?

Before you consider Rhythm Biosensors, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Rhythm Biosensors wasn't one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares